PYC Therapeutics Advances PYC-001 to Multiple Dose Study for Blinding Eye Disease ADOA
PYC Therapeutics has secured Safety Review Committee approval to escalate dosing of its investigational drug PYC-001 for Autosomal Dominant Optic Atrophy from single to multiple doses, marking a key step in its clinical development.
- Safety Review Committee approves 60 microgram dose for multiple ascending dose study
- Phase 1/2 trial to assess repeated dosing safety and efficacy in ADOA patients
- Data readouts expected throughout 2026 and 2027
- Progression supports global registrational trial plans
- Advancement follows recent capital raises to fund pipeline development
Safety Milestone Unlocks Next Phase for PYC-001
PYC Therapeutics (ASX:PYC) has cleared an important clinical hurdle in its quest to tackle Autosomal Dominant Optic Atrophy (ADOA), a rare genetic eye disorder that currently has no approved treatments. The Safety Review Committee overseeing the Phase 1 Single Ascending Dose (SAD) study has given the green light to progress the 60 microgram dose of PYC-001 into a multiple ascending dose (MAD) study. This decision follows a four-week safety and tolerability review, signalling that repeated dosing at this level is deemed safe enough to continue testing.
Expanding the Clinical Trial Scope
The shift to a MAD study means PYC will now evaluate the safety and efficacy of repeated 60 microgram doses alongside the existing 10 and 30 microgram cohorts in its ongoing Phase 1/2 trial. This broader dosing strategy aims to establish clinical proof-of-concept, a critical step before moving into a global registrational trial intended to support a New Drug Application for PYC-001 in ADOA. The company plans to release safety and efficacy data intermittently across 2026 and 2027, offering investors and observers a timeline for upcoming milestones.
PYC is navigating this development amid a busy period of capital raising, having recently secured $47 million through a retail entitlement offer to bolster its clinical programs. This funding infusion complements the earlier substantial $653 million capital raise designed to extend its cash runway through to 2030, underpinning the advancement of its RNA therapeutic pipeline. These financial moves provide a sturdy foundation as PYC pushes PYC-001 through increasingly complex trial phases, reflecting the company’s commitment to translating RNA therapies into tangible patient benefits.
Targeting a Rare and Unmet Medical Need
ADOA affects approximately one in every 35,000 people and leads to progressive vision loss due to degeneration of the optic nerve. PYC-001 is designed to address the underlying genetic cause of this blinding disease, positioning it within a niche but high-impact therapeutic area. The company’s proprietary RNA delivery platform aims to enhance the precision and potency of its therapies, which target monogenic diseases with a higher likelihood of clinical success.
While the Safety Review Committee’s approval is a positive development, the multiple ascending dose study remains subject to regulatory and ethics approvals, and no efficacy data has yet been disclosed. The coming months will be critical for PYC to demonstrate that repeated dosing can safely translate into meaningful clinical outcomes for patients.
Bottom Line?
PYC’s progression to multiple dosing in ADOA trials marks a pivotal step, but upcoming efficacy data will be crucial to validate clinical promise.
Questions in the middle?
- Will repeated dosing of PYC-001 demonstrate measurable efficacy in slowing or reversing ADOA progression?
- How will regulatory and ethics approvals impact the timeline for the global registrational trial?
- What competitive landscape and market dynamics will PYC face in developing the first approved treatment for ADOA?
